Categories
Health

Sacklers Threaten to Pull Out of Opioid Settlement With out Broad Authorized Immunity

At least 2,700 lawsuits and hundreds of thousands of lawsuits have been registered against Purdue, beginning in 2014 when the opioid epidemic peaked. Plaintiffs span a broad spectrum including 48 states, local governments, tribes, hospitals, individuals and caregivers of infants born with symptoms of withdrawal from opioids, all of whom are devastated and financially exhausted from opioids.

In the last few years, more and more cases, individual sackers have been named themselves.

Nearly two years ago, Purdue filed for bankruptcy restructuring that automatically suspended those lawsuits. However, the Sacklers themselves did not file for bankruptcy, despite insisting that they too benefit from their company’s expected indemnities.

The issue of releases for the Sacklers and other third parties is at the center of opposition to the bankruptcy scheme that is now being pursued by nine states, including Maryland, Washington and Connecticut. The District of Columbia, the Federal Department of Justice and the U.S. Trustee, a Department of Justice program that monitors bankruptcy cases, as well as several Canadian local governments and First Nations have joined in the opposition.

Under applicable law of the Second Circuit Court of Appeals, where the Judge Drain Court is located, the judge may grant exemptions to the Sacklers and other third parties who have not filed for bankruptcy. But, by and large, the issue is unresolved.

Other federal districts prohibit it. The issue has been taken up by members of Congress and could well lead to an appeal by the opponents if Judge Drain approves the plan. The pounding questions of contradicting attorneys so far should not only raise questions about the plan, but lay a foundation for such appeals.

Alain Delaquérière contributed to the research.

Categories
Health

Pfizer and Moderna Vaccines Prone to Produce Lasting Immunity, Research Finds

The vaccines from Pfizer-BioNTech and Moderna trigger a sustained immune response in the body that can protect against the coronavirus for years, scientists reported on Monday.

The results add to the growing evidence that most people immunized with the mRNA vaccines may not need a booster dose as long as the virus and its variants do not progress much beyond their current forms – which is not guaranteed. People who have recovered from Covid-19 before they were vaccinated may not need a booster vaccination, even if the virus goes through a significant transformation.

“It’s a good sign of how persistent our immunity to this vaccine is,” said Ali Ellebedy, an immunologist at Washington University in St. Louis who led the study, which was published in the journal Nature.

The study did not take into account the coronavirus vaccine manufactured by Johnson & Johnson, but Dr. Ellebedy said he believed the immune response was less permanent than that of mRNA vaccines.

Dr. Ellebedy and colleagues reported last month that in people who survived Covid-19, immune cells that recognize the virus remain dormant in the bone marrow for at least eight months after infection. A study by another team showed that so-called memory B cells continue to mature and strengthen for at least a year after infection.

Based on these results, the researchers suggested that immunity in people infected with the coronavirus and later vaccinated could last for years, possibly a lifetime. However, it was unclear whether vaccination alone could have a similar long-lasting effect.

Dr. Ellebedy addressed this question by examining the source of memory cells: the lymph nodes, where immune cells train to recognize and fight the virus.

After an infection or vaccination, a specialized structure forms in the lymph nodes, the germinal center. This structure is sort of an elite school for B cells – a boot camp in which they become increasingly sophisticated and learn to recognize a multitude of viral genetic sequences.

The greater the range and the longer these cells have to practice, the more likely they are to thwart any virus variants that may appear.

“Everyone is always focused on developing the virus – this shows that the B cells are doing the same,” said Marion Pepper, an immunologist at the University of Washington in Seattle. “And it will protect against the continued development of the virus, which is really encouraging.”

After an infection with the coronavirus, the germinal center forms in the lungs. But after the vaccination, the cells are formed in the lymph nodes in the armpits that researchers can reach.

Updated

July 2, 2021, 5:06 p.m. ET

Dr. Ellebedy and colleagues recruited 41 people – including eight with a history of infection with the virus – who were immunized with two doses of the Pfizer BioNTech vaccine. The team collected lymph node samples from 14 of these people three, four, five, seven and 15 weeks after the first dose.

This meticulous work makes this a “heroic study,” said Akiko Iwasaki, an immunologist at Yale. “This kind of careful time history analysis in humans is very difficult.”

Dr. Ellebedy found that 15 weeks after the first dose of the vaccine, the germinal center was still highly active in all 14 participants and that the number of memory cells that recognized the coronavirus had not decreased.

“The fact that the reactions lasted almost four months after the vaccination – that’s a very, very good sign,” said Dr. Ellebedy. Sprouting centers typically peak one to two weeks after vaccination and then decrease.

“Usually there isn’t much left after four to six weeks,” said Deepta Bhattacharya, an immunologist at the University of Arizona. But germinal centers that are stimulated by the mRNA vaccines “still go in, months, and most people don’t go back much”.

Dr. Bhattacharya noted that most of what scientists know about the persistence of germinal centers is based on animal studies. The new study shows for the first time what happens to people after vaccination.

The results suggest that the vast majority of those vaccinated will be protected in the long term – at least against the existing coronavirus variants. But older adults, people with weak immune systems, and those taking drugs that suppress immunity may need boosters; People who survived Covid-19 and were later vaccinated may not need it at all.

It is difficult to predict exactly how long protection against mRNA vaccines will last. In the absence of variants that bypass immunity, immunity could theoretically last a lifetime, experts said. But the virus is clearly evolving.

“Anything that would actually require a refresher would be variant-based, not immunity waning,” said Dr. Bhattacharya. “I just don’t see it.”

People who have been infected with the coronavirus and then immunized see a sharp spike in their antibody levels, likely because their memory B cells – which produce antibodies – had many months to develop before vaccination.

The good news: a booster vaccine is likely to have the same effect on people who have been vaccinated as a previous infection, said Dr. Ellebedy. “If you give them another chance to get involved, they’ll have a massive response,” he said, referring to memory B cells.

In terms of boosting the immune system, vaccination is “probably better” than recovering from the actual infection, he said. Other studies have shown that the repertoire of memory B cells produced after vaccination is more diverse than that produced by infection, suggesting that the vaccines protect against variants better than natural immunity alone.

Dr. Ellebedy said the results also suggest that these signs of sustained immune response could be caused by mRNA vaccines alone, as opposed to those made by more traditional means like Johnson & Johnson’s.

But that’s an unfair comparison because the Johnson & Johnson vaccine is given as a single dose, said Dr. Iwasaki: “If the J&J had a booster, they might get the same kind of reaction.”

Categories
Health

South Korea on Covid-19 herd immunity and journey bubble packages

Customers wearing protective masks pay for their purchase at a vegetable stall in Mangwon Market in Seoul, South Korea on Tuesday, February 9, 2021.

Bloomberg | Bloomberg | Getty Images

South Korea wants to open up its economy and work on travel bubble programs as it has been relatively successful in controlling the spread of Covid-19, its deputy prime minister told CNBC in an exclusive interview.

The government plans to boost consumption and further boost the economy in the second half of this year – and steps are being taken to achieve that goal, said Hong Nam-ki, who is also South Korea’s economy and finance minister.

“I would say the current government has been relatively successful at both infection control and vaccination,” he told CNBC’s Chery Kang on Friday, according to a CNBC translation of his Korean remarks. “Based on the achievements, the current government now wants to promote economic growth while maintaining such health measures.”

In fact, he said that South Korea is aiming for herd immunity by November, which means the virus will no longer be able to spread rapidly as most of the population is either fully vaccinated or has become immune from infection.

By last week, 30% of the South Korean population had received their vaccinations and Hong says the country can reach 70% by September.

Our plan now is to achieve herd immunity by November – but in my personal opinion we will be able to move the schedule forward.

Hong Nam-ki

South Korea’s Deputy Prime Minister

The country has reported more than 155,500 cases and at least 2,015 deaths as of Monday, according to Johns Hopkins University – numbers that are relatively controlled compared to most Asian countries.

In contrast, India – with the highest number of cases in Asia – officially reported more than 30.2 million cases on Monday, according to Hopkins. Indonesia has 2.11 million cases while the Philippines has nearly 1.4 million case numbers, the data showed.

“Our plan now is to achieve herd immunity by November – but in my personal opinion we will be able to move the schedule forward,” said Hong.

“If the vaccination goes as planned, we believe the Covid-19 situation is under control. Then the measures to support consumption and economic recovery can be carried out without interruption from July onwards.

However, should the pandemic worsen, it would be difficult to push these growth-promoting measures, he warned.

Travel bubble?

The South Korean government plans to support travel bladder programs for fully vaccinated people, Hong said. A travel bubble is a pre-agreed agreement with another country that provides that travelers from both countries are allowed quarantine trips if certain conditions are met – such as negative Covid tests or full vaccinations.

However, whether the travel bubble will pop depends on vaccination progress and conversations with other countries, he said, declining to name those countries.

In early June, the Singaporean newspaper Straits Times reported that South Korea is exploring travel bladders with some countries, including Singapore and Taiwan, to enable quarantine-free travel for vaccinated people.

“I believe that depending on their health status, vaccination rates and the convenience of immigration, more countries will be on the list of countries in demand,” Hong told CNBC.

“I think we need to continue working with private tour operators to investigate the virus situation to decide exactly which countries,” he added.

One initiative that citizens can at least indulge in for the time being could be “flights to nowhere”, a target-free concept that some countries introduced during the pandemic.

“Even if you cannot travel abroad, no landing flights have been offered,” said Hong. “Passengers could fly all the way to Japan, hover over the Japanese sky, and then come back without landing. Lots of people showed interest in it and it was used a lot, ”he said, referring to such flights that were introduced in South Korea last year.

“So if the health situation improves and the vaccination campaign accelerates more strongly, we believe that we are going in (that) direction.”

Categories
Health

Immunity to the Coronavirus Might Persist for Years, Scientists Discover

Immunity to the coronavirus lasts at least a year, possibly a lifetime, and improves over time, especially after vaccination, according to two new studies. The results could help dispel lingering fears that protection from the virus will be short-lived.

Taken together, the studies suggest that most people who have recovered from Covid-19 and were later immunized don’t need boosters. However, vaccinated people, who most likely never got infected, need the shots, as do a minority who were infected but did not evoke a robust immune response.

Both reports looked at people who had been exposed to the coronavirus about a year earlier. Cells that hold a memory for the virus remain in the bone marrow and can produce antibodies when needed, according to one of the studies published in Nature on Monday.

The other study, which is also being examined for publication in Nature, found that these so-called memory B cells continue to mature and strengthen at least 12 months after the initial infection.

“The publications are consistent with the growing body of literature suggesting that immunity induced by infection and vaccination against SARS-CoV-2 appears to be long-lasting,” said Scott Hensley, an immunologist at the University of Pennsylvania, who was not involved in the research.

The studies could allay fears that immunity to the virus is temporary, as is the case with coronaviruses, which cause colds. But these viruses change significantly every few years, said Dr. Hensley. “The reason we become repeatedly infected with frequent coronaviruses over the course of life could have a lot more to do with the variation in these viruses than with immunity,” he said.

In fact, memory B cells, which were produced in response to SARS-CoV-2 infection and boosted by vaccination, are so effective that they even thwart variants of the virus and nullify the need for boosters, according to Michel Nussenzweig, immunologist at Rockefeller University in New York, who led the study on memory maturation.

“People who have been infected and vaccinated really have a great response, a great set of antibodies, because they keep developing their antibodies,” said Dr. Nut branch. “I assume they will last a long time.”

The result may not only apply to vaccine protection, as immune memory is likely to be organized differently after immunization than after natural infection.

That means people who haven’t had Covid-19 and have been vaccinated may need a booster shot, said Dr. Nut branch. “We’ll know something like that very, very soon,” he said.

When a virus first appears, B cells multiply quickly and produce antibodies in large quantities. Once the acute infection has subsided, a small number of cells take their place in the bone marrow and steadily pump out modest amounts of antibodies.

To study the memory B cells specific to the new coronavirus, researchers led by Ali Ellebedy of Washington University in St. Louis analyzed the blood of 77 people at three-month intervals, starting about a month after they were infected the coronavirus. Only six of the 77 had been hospitalized for Covid-19; The rest had mild symptoms.

Antibody levels in these people fell rapidly four months after infection and then slowly decreased for months afterward – results that are in line with other studies.

Some scientists have interpreted this drop as a sign of waning immunity, but it’s exactly what is expected, other experts said. If blood contained large amounts of antibodies to every pathogen the body had ever encountered, it would quickly turn into thick mud.

Updated

May 26, 2021, 11:32 a.m. ET

Instead, blood levels of antibodies drop sharply after an acute infection, while memory B cells in the bone marrow remain calm and ready to take action if necessary.

Dr. Ellebedy received bone marrow samples from 19 people approximately seven months after infection. Fifteen had detectable storage B cells but four did not, suggesting that some people may have very few cells or no cells at all.

“It tells me that even if you got infected, it doesn’t mean you have a super immune response,” said Dr. Ellebedy. The results confirm the idea that people who have recovered from Covid-19 should be vaccinated, he said.

Five of the participants in Dr. Ellebedy’s study donated bone marrow samples seven or eight months after the initial infection and again four months later. He and his colleagues found that the number of storage B cells remained stable over this time.

The results are especially noteworthy given that bone marrow samples are difficult to obtain, said Jennifer Gommerman, an immunologist at the University of Toronto who was not involved in the work.

A landmark 2007 study showed that antibodies can theoretically survive for decades, perhaps well beyond the average lifespan, suggesting the long-term existence of memory B cells. But the new study offered rare evidence of its existence, said Dr. Gommerman.

Dr. Nussenzweig studied how memory B cells mature over time. The researchers analyzed the blood of 63 people who had recovered from Covid-19 about a year earlier. The vast majority of participants had mild symptoms and 26 had also received at least one dose of the Moderna or Pfizer BioNTech vaccine.

So-called neutralizing antibodies, which were needed to prevent re-infection with the virus, remained unchanged between six and twelve months, while related but less important antibodies slowly disappeared, the team found.

As memory B cells evolved, the antibodies they produced developed the ability to neutralize an even wider group of variants. This continued maturation may be due to a small piece of the virus being bound by the immune system – for target practice, so to speak.

One year after infection, the neutralizing activity was lower in the non-vaccinated participants compared to all forms of the virus, with the greatest loss being recorded compared to the variant first identified in South Africa.

The vaccination significantly increased antibody levels and confirmed the results of other studies. The shots also increased the body’s ability to neutralize by 50 times.

Kentucky Republican Senator Rand Paul said Sunday he would not receive a coronavirus vaccine because he was infected last March and was therefore immune.

However, there is no guarantee that such immunity will be strong enough to protect him for years, especially given the emergence of variants of the coronavirus that can partially bypass the body’s defenses.

The results of the study by Dr. Nussenzweig suggest that people who have recovered from Covid-19 and were later vaccinated will continue to have extremely high levels of protection against emerging variants, even without receiving a vaccine booster later.

“It looks exactly what we’d hope a good memory B-cell response would look like,” said Marion Pepper, an immunologist at the University of Washington in Seattle who was not involved in the new research.

All experts agreed that immunity in people who have never had Covid-19 is likely to vary widely. Fighting a live virus is different from responding to a single viral protein introduced by a vaccine. And in those who had Covid-19, the initial immune response had time to mature over six to 12 months before being challenged by the vaccine.

“These kinetics are different from someone who has been immunized and re-immunized three weeks later,” said Dr. Pepper. “That doesn’t mean they might not have that broad answer, but it could be very different.”

Categories
Health

Is herd immunity potential? New Covid vairants could possibly be an issue

Passengers wearing face masks as a preventive measure against the spread of Covid-19 are seen on an escalator at Orlando International Airport.

Paul Hennessy | LightRocket | Getty Images

When the coronavirus pandemic broke out around the world in 2020, a number of governments and health officials seemed to be pinning their hopes on “herd immunity”.

This approach would cause the virus to spread through society and cause infection, but it would also create an immune response in those who have recovered.

If enough people received these antibodies – around 60-70% of the population – transmission of the virus would gradually decrease, and those who were not yet infected would be protected by the increasingly limited ability of the virus to spread.

That was the theory.

In reality, Covid-19 swept through Asia, Europe and America, causing millions of infections – from which millions of people recovered – but also hundreds of thousands of hospitalizations and deaths. To date, the virus has caused over 164 million infections and 3.4 million deaths worldwide.

The herd immunity strategy was quickly abandoned by most countries – with a few notable exceptions such as Sweden – and lockdowns became the main way to prevent the spread of Covid as vaccines developed rapidly.

Now we have highly effective vaccines and vaccination programs are advancing around the world. This has raised hope that once enough people in populations are vaccinated, herd immunity could be achieved – that is, if enough people are vaccinated, the virus has nowhere to go and become extinct.

But again, Covid-19 is proving unpredictable and we still don’t know how long the protection from vaccines or the natural immunity acquired from previous infections will last.

The hesitation of the vaccine, the role of children in transmission (infants are not eligible for vaccines) and most importantly the emergence of new variants of Covid around the world are also unknowns that could also prevent herd immunity, experts warn.

Most of them believe that Covid-19 will become endemic like the flu (meaning it will continue to circulate in parts of the population, likely as a seasonal threat) while hoping it will become less dangerous over time.

“Nowhere near herd immunity”

Epidemiologist Lauren Ancel Meyers, director of the University of Texas’ Covid-19 modeling consortium, described herd immunity as “the idea that if we vaccinate enough people around the world, the virus has nowhere to spread, and the pandemic will go away completely.” ” “”

“Unfortunately, we are very far from this reality worldwide,” she told CNBC.

“The virus continues to spread rapidly across many continents, more contagious varieties are emerging all the time that can potentially breach immunity, and many countries are lagging far behind the US in adopting vaccines.”

She noted that even in US cities there are critical areas of low immunity: “Where I live in Austin, Texas, we estimate the vaccination rate is between under 40% and over 80%, depending on the neighborhood in which you are Everywhere children under the age of 12 cannot be vaccinated. As long as there are pockets with low immunity, this secret virus will continue to spread and produce new variants. “

Even so, Meyers noted that “vaccines can help us get to a place where Covid-19 is a significantly less lethal threat,” even if we fail to achieve full herd immunity.

According to Meyers, there has been a lot of misinformation and misunderstanding about the herd immunity threshold. “Put simply, the herd immunity threshold is the percentage of the population that needs to be immunized before the virus goes away. In the real world, however, this is complicated.”

“With variants and low-vaccination bags emerging, there is no guarantee we will get there,” she said, noting the importance of people realizing, “The more people vaccinate, the faster the threat will fade . “

“We may never reach herd immunity and completely eradicate the virus on a global scale. However, that doesn’t mean we won’t return to a sense of normality anytime soon. We are already seeing the number of new cases and hospitalizations falling,” added Meyers added.

Challenging strategy

After a year, the coronavirus has experienced some significant mutations and a number of variants have become dominant due to their increased transmissibility – like those first detected in the UK and South Africa last year.

Now a variant first discovered in India in October 2020 is raging across the country and beyond. As with previous mutations, experts are investigating whether it could make it more transmissible (early evidence suggests), more lethal (early evidence suggests), and Covid vaccines less effective (early evidence suggests).

Professor Lawrence Young, a virologist at the University of Warwick Medical School in the UK, told CNBC that the pursuit of herd immunity in relation to Covid-19 is unlikely to be achievable.

“The pursuit of herd immunity in terms of people getting infected and then recovering is not great, as Sars-Cov-2 obviously has people getting sick – but it’s also about what the herd immunity threshold is and what percentage of it Population would they need to be protected? And that depends so much on the transmittability of the virus, “noted Young.

“We are dealing with variants that have different spreading abilities and I think that makes it quite difficult to achieve herd immunity or to rely on herd immunity.”

He emphasized that there are still many “unknowns” about Covid-19.

“And I think it’s going to be impossible to get herd immunity through vaccination. Variants and the fact that you don’t necessarily get lifelong immune protection after vaccination make it more difficult,” Young said.

When asked if there is any chance the coronavirus could be eradicated, Young said, “It won’t happen.”

“We’re going to have to live with it, like the flu, and we just have to get so many people vaccinated to keep them from getting sick.”

Categories
Health

Reaching ‘Herd Immunity’ Is Unlikely within the U.S., Specialists Now Consider

The skepticism of many Americans about the vaccines and the lack of access in some groups – homeless, migrant workers, or some color communities – make it a challenge to achieve this goal. Vaccine mandates only make this attitude worse, some experts believe.

A better approach would be to have a trustworthy person address the root cause of hesitation – fear, suspicion, misunderstanding, easy access, or a desire for more information, said Mary Politi, an expert on health decisions and communication at Washington University in St. Louis.

People often need to see others in their social circle accept something before they’re ready to try, said Dr. Politi. Highlighting the life benefits of vaccination, like seeing a family member or sending their children to school, might be more motivating than the nebulous idea of ​​herd immunity.

“That would resonate more with people than that somewhat elusive concept that experts are still trying to figure out,” she added.

Although children spread the virus less efficiently than adults, all experts agreed that vaccinating children would also be important in keeping the number of Covid cases down. In the long term, the public health system must also take into account babies and children and adults who fall into a higher risk group.

Annoying scenarios remain on the way to this long-term vision.

If enough people are not protected over time, highly contagious variants can develop that can breach vaccine protection, bring people to the hospital, and put them at risk of death.

“This is the nightmare scenario,” said Jeffrey Shaman, an epidemiologist at Columbia University.

How common and how severe these breakthrough infections are may determine whether the United States can keep hospital stays and deaths down, or whether the country is in “maddening turmoil” every few years, he said.

Categories
Health

Reaching ‘Herd Immunity’ Is Unlikely within the U.S., Specialists Now Consider

A better approach would be to have a trustworthy person address the root cause of hesitation – fear, suspicion, misunderstanding, easy access, or a desire for more information, said Mary Politi, an expert on health decisions and communication at Washington University in St. Louis.

People often need to see others in their social circle accept something before they’re ready to try, said Dr. Politi. Highlighting the life benefits of vaccination, like seeing a family member or sending their children to school, might be more motivating than the nebulous idea of ​​herd immunity.

“That would resonate more with people than that somewhat elusive concept that experts are still trying to figure out,” she added.

Although children spread the virus less efficiently than adults, all experts agreed that vaccinating children would also be important in keeping the number of Covid cases down. In the long term, the public health system must also take into account babies and children and adults who fall into a higher risk group.

Annoying scenarios remain on the way to this long-term vision.

If enough people are not protected over time, highly contagious variants can develop that can breach vaccine protection, bring people to the hospital, and put them at risk of death.

“This is the nightmare scenario,” said Jeffrey Shaman, an epidemiologist at Columbia University.

How common and how severe these breakthrough infections are may determine whether the United States can keep hospital stays and deaths down, or whether the country is in “maddening turmoil” every few years, he said.

“I think we’re going to look over our shoulders – or at least, public health officials and infectious disease epidemiologists will look over their shoulders and say, ‘Okay, the varieties out there – what are they doing? What can you? ” he said. “Maybe the general public can’t care too much about it again, but we have to.”

Categories
Health

U.S. could by no means attain ‘true herd immunity,’ says Dr. Scott Gottlieb

Dr. Scott Gottlieb told CNBC on Friday he believes the United States may struggle to achieve “true herd immunity” to Covid, suggesting there will be coronavirus infections in the years to come.

However, the former commissioner of the U.S. Food and Drug Administration stressed that new cases alone should not be the metric that gets the greatest focus as more people are vaccinated against Covid.

“I don’t think we should think about achieving herd immunity. I don’t know that we will ever achieve real herd immunity where this virus simply no longer circulates,” said Gottlieb at “Closing Bell”. “I think it will always be circulating at low levels. That should be the goal of keeping virus levels down.”

Gottlieb, who serves on the board of directors at Covid vaccine maker Pfizer, expects the US to make significant strides toward that goal in the coming weeks.

“I think we’ll reach a point this summer where the spread of this virus will be extremely low. We’ll likely see the cases collapse pretty soon sometime in May. We’re already seeing it in parts of the country.” said Gottlieb.

Even so, according to Gottlieb, the US could flatten about 5,000 to 10,000 new coronavirus cases per day this summer, partly due to how commonplace Covid testing has become. “We’re going to see a lot of asymptomatic and mildly symptomatic infections,” he said.

“I think the bottom line is that vaccination is dramatically reducing the susceptibility of the American population, and that’s what we really need to focus on,” said Gottlieb, who headed the FDA in the Trump administration from 2017 to 2019.

“We shouldn’t just focus on cases. There will be cases, but we should focus on how many people are hospitalized and get this virus. That will drop dramatically when we introduce the vaccines,” he said.

Public health experts have stressed throughout the pandemic that the more people in a population have immunity protection for a particular virus, the less easily it will spread. While vaccines have been shown to reduce transmission, Gottlieb isn’t the first to point out that achieving permanent herd immunity is likely to be a challenge for Covid.

The Chief Medical Officer of the White House, Dr. Anthony Fauci, has estimated that 75% to 85% of the population vaccinated against Covid would create an “umbrella” of immunity. “That could even protect the vulnerabilities that weren’t vaccinated or where the vaccine wasn’t effective,” he told CNBC in December, shortly after the FDA approved Pfizer’s emergency use of Pfizer.

About 41% of the US population have now received at least one dose of Covid vaccine, and 27.5% are fully vaccinated, according to the latest information from the Centers for Disease Control and Prevention. CDC data show that a total of more than 220 million doses were administered.

Gottlieb previously said that the US could theoretically get to a point where Covid, like other diseases like polio and smallpox, will be eradicated. “It is possible. We do not seem ready to do this and take the collective action that is required,” he told CNBC on April 16.

“It will take people who practice a civic virtue to get vaccinated, even if they individually feel low risk of infection,” he said. “Because even if they are at low risk, they can still get and transmit the infection, and you cannot eradicate a disease where you have a significant contingent of people who will continue to catch and transmit it.”

Disclosure: Scott Gottlieb is a CNBC employee and a member of the boards of directors of Pfizer, genetic testing startup Tempus, health technology company Aetion Inc., and biotech company Illumina. He is also co-chair of Norwegian Cruise Line Holdings and Royal Caribbean’s Healthy Sail Panel.

Categories
Business

Scientist who helped develop Pfizer-BioNTech Covid vaccine agrees third shot is required as immunity wanes

BioNTech’s chief medical officer told CNBC on Wednesday that people will likely need a third shot of its two-dose Covid-19 vaccine to lower immunity to the virus. This is in line with previous comments from Pfizer CEO Albert Bourla.

Dr. Ozlem Tureci, co-founder and CMO of BioNTech, who developed a Covid vaccine together with Pfizer, also assumes that people need to be vaccinated against the coronavirus every year, for example against seasonal flu. That’s because scientists expect vaccine-induced immunity to the virus to decline over time.

“We see evidence of this in the induced, but also natural, immune response against SARS-COV-2,” she said during an interview with Kelly Evans of CNBC in “The Exchange”. “We see this decrease in immune responses also in people who have just been infected and therefore [it’s] also expected with the vaccines. “

Tureci’s comments come after Pfizer CEO Albert Bourla said in an interview broadcast on April 15 that people will likely need a booster shot or third dose of the Covid-19 vaccine within 12 months of being fully vaccinated. He also said that there is a possibility that people will have to take extra shots every year.

Pfizer said earlier this month that its Covid-19 vaccine was more than 91% effective against the virus and more than 95% effective against serious illness up to six months after the second dose. Moderna’s vaccine, which uses technology similar to Pfizer, has also been shown to remain highly effective after six months.

The researchers say they still don’t know how long protection against the virus will last after six months of full vaccination, although public health officials and health experts believe that protection will wear off after some time.

Should Americans need booster vaccinations, the US government would likely need to reach agreements with drug manufacturers to provide additional doses and make plans to distribute vaccines.

On Friday Andy Slavitt, senior advisor to President Joe Biden’s Covid Response Team, said the Biden administration was preparing for the potential need for Covid-19 vaccine booster shots. He said the government was considering the need to secure additional doses.

“I can assure you that as we plan, if the President orders the purchase of additional vaccines, as he has, and if we focus on all of the production expansion opportunities that we are talking about, we have a great many such scenarios in mind have. “he said.

Last week, David Kessler, chief science officer for the Biden government at Covid, said Americans should expect to receive booster vaccinations to protect against coronavirus variants. He told US lawmakers that currently approved vaccines offer high levels of protection, but that new variants may “question” the effectiveness of the shots.

“We don’t know everything right now,” he told the House Select subcommittee on the coronavirus crisis.

“We are investigating the durability of the antibody response,” he said. “It seems strong, but that’s wearing off a bit, and no doubt the variants are challenging … they make these vaccines work harder. So I think for planning purposes, planning purposes only, we should expect us to may have to. ” Boost. “

Stephane Bancel, CEO of Moderna, told CNBC last week that the company hopes to have a booster shot for its two-dose vaccine in the fall.

Categories
Health

Consultants talk about if it is attainable to succeed in Covid immunity

People hold hands on Fifth Avenue amid the coronavirus pandemic on April 10, 2021 in New York City.

Noam Galai | Getty Images Entertainment | Getty Images

As Covid vaccines roll out around the world, many look forward to “herd immunity” – when the disease stops spreading quickly because the majority of the population is immune from vaccination or infection.

It is seen as a path to normalcy and something doctors and political leaders often discuss when talking about defeating Covid-19.

While there have been doubts as to whether herd immunity is possible, medical experts who have spoken to CNBC say it can be achieved. However, they point to a difficult path, as maintaining high levels of immunity will be a challenge.

“I think every part of the world will sooner or later reach herd immunity,” said Benjamin Cowling, director of the epidemiology and biostatistics department at the University of Hong Kong’s School of Public Health. Different communities could get there through vaccinations, infection, or a combination of both, he added.

Not everyone agrees.

An article last month in Nature identified five reasons herd immunity might not be possible. According to the report, the barriers to herd immunity include: new varieties, dwindling immunity, and questions about whether vaccines actually prevent transmission.

Shweta Bansal, a math biologist, told the publication, “Herd immunity is only relevant if we have a vaccine that blocks transmission. If we don’t, the only way to get herd immunity in the population is by to give everyone the vaccine. “”

Herd immunity: “Complicated” but possible

Health experts who spoke to CNBC have recognized that the factors raised in the article on nature could hinder progress toward herd immunity – but they believe that is still within reach.

“We’re not trying to eradicate it, we’re trying to stop the runaway community transmission. In that sense, we can achieve (herd immunity),” said Dale Fisher, professor of infectious diseases at the National University of Singapore’s Yong Loo Lin School of Medicine.

Dr. Anthony Fauci, chief medical officer to President Joe Biden, said 75% to 85% of people need to be vaccinated to create an “umbrella” of immunity that will prevent the virus from spreading. Fisher estimates the number is around 70%.

“Reaching 70% is possible, but there are many threats,” he said, explaining that the percentage of a population immune to Covid-19 would decrease as immunity wears off. make the vaccines less effective.

“Herd immunity is something very nice and conceptual, but it’s more complicated,” he said during a call. “If you want to call a magic number around 70% then all I am saying is very hard to come by and maintain.”

Herd immunity may not be permanent, but rather short-term.

Benjamin Cowling

School of Public Health at the University of Hong Kong

Cowling agreed that there is “no guarantee” that immunity levels would remain high over the long term. “Herd immunity may not be permanent, but rather short-term,” he said.

Still, it’s something the world can work towards, he added, emphasizing that refresher shots can help when protection is lost.

Back to the “normal”

It could take three to five years for the world to return to “completely normal,” said Carlos del Rio, a professor of medicine at Emory University School of Medicine.

“There are still a lot of broadcasts around the world and I think it will be some time before that changes,” he told CNBC’s Street Signs Asia on Monday.

The World Health Organization warned this week that the pandemic is “growing exponentially” and more than 4.4 million new Covid-19 cases have been reported in the past week.

The agency’s technical director for Covid-19, Maria Van Kerkhove, said the world has reached “a critical point in the pandemic”.

“Vaccines and vaccinations are going online, but they are not yet available in all parts of the world,” she added.

Fisher said the world is still “very susceptible to large outbreaks” – but cases could sporadic in five or ten years. In the meantime there will be a transition period.

“Herd immunity is not a binary phenomenon,” he said. “Most people think you either have it or you don’t – but it’s obviously gray in between.”

Cowling said he thinks the greatest risk for Covid will be in the next 12 months, but the threat will decrease afterwards as vaccines are introduced.

“What I would expect in the years to come is that the virus will still circulate, it will be endemic, but it will no longer be a major threat to public health,” he said.

– CNBC’s Berkeley Lovelace contributed to this report.